🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Credits : Eric K. Singhi, MD #lcsm

The #TolAlgorithm for treating HR+/HER2- MBC in (the first half of) 2025 Sara Tolaney #ESMOBreast25 #esmoambassadors

#ESMOBreast25 Metastatic HR+/HER2- Breast Cancer: An Evolving Approach From Dr. Seth Wander's amazing presentation👇 #ESMOAmbassadors ESMO - Eur. Oncology

📘Management of testicular cancer JCO Oncology Practice ASCO 👉doi.org/10.1200/OP-25-… OncoAlert #cancer #oncology #MedX

🆕JUST IN🆙 🔥HARMONi positive PFS, positive trends in OS 💉Ivonescimab (SMT112, AK112): PD-1 x VEGF 🎯PFS HR 0.52 (95%CI: 0.41-0.66), statistically positive 🎯OS HR 0.79 (95%CI: 0.62-1.01),primary analysis 🎙️ Summit Therapeutics smmttx.com/pressrelease/h… #LCSM OncoAlert LARVOL

And the fun starts! From @asco #asco25 press release Overall survival was 30.3 months in the encorafenib/cetuximab with mFOLFOX6 arm, 19.5 months in the encorafenib/cetuximab alone arm, and 15.1 months in the control arm. PFS pic below NEJM asco.org/about-asco/pre…

📌Cytotoxic Therapy in Metastatic Hormone-Receptor Breast Cancer: Antibody-Drug Conjugates and Chemotherapy in Focus #ASCO25 OncoAlert #OncoAlertAF

Colon Cancer Updated Algorithm Credits : Oncology Brothers #ASCO25 #GIOnc

🫁 Resectable #NSCLC—an area where we have seen a lot of scientific developments! 💥 Big updates coming at #ASCO25 today! 👇 Here’s a refresher on where we stand today! 🔍 Let’s see how the treatment landscape may evolve 🌄, looking forward to a great session today!

Slide updated! ✔️ Looking forward to the presentation here at #ASCO25 ASCO

💡 After 2 oral presentations that definitively change the treatment landscape and impacts in survival for patients with ES-SCLC (any of them, if not both, should have been plenary ASCO this year), the key question here is: when will we have access to lurbinectedin and

This is data many of who treat the highest risk young patients (N2-3) have waited for for a while! This ahould have been an oral #ASCO2025 Ann Partridge MD, MPH #bcsm

Excellent summary slides for current evidence for pancreatic cancer treatment . Useful for quick reference. @asco #asco25 taken from talk by Dr Brian Wolpin 👍OncoAlert ONCO BRUNO

#ASCO2025 was filled with groundbreaking science. Feeling inspired and grateful to be part of this community. These are just a few of the top breast cancer studies presented, and some of the remaining questions.

🔄 #ASCO25 REVIEW🔁 ☑️Tough Choices: Front-Line Treatment Dilemmas in EGFR Metastatic Non–Small Cell Lung Cancer 🔥Osimertinib Alone as Front-Line Therapy 🎙️ Julia Rotow MD OncoAlert ASCO EGFR Resisters meetings.asco.org/2025-asco-annu…

mNSCLC treatment evolving rapidly! 📈 New targets & treatments emerging every day.A must-have guide for busy practitioners! 💡 Ready reckoner for staying up-to-date! #mNSCLC #Oncology #MedicalUpdate

📢 A new era in head & neck cancer care begins. #FDA approves #pembrolizumab as the first immunotherapy for perioperative use in resectable LA-HNSCC. Neoadjuvant + adjuvant strategy now reshapes standard of care. 👇See the full breakdown: 📊 #KEYNOTE689 | 📆 June 12, 2025

🎯 Testicular cancer is the most common solid tumor in young men (15–40y), with >90% being germ cell tumors (GCTs). Early diagnosis + tailored treatment = excellent outcomes (5y OS: 99% in stage I). Survivorship matters 👉🏻 fertility, CV risk & QoL must guide care. 📖

Practical HCC treatment algorithm guiding choices from early-stage to systemic disease. More than a flowchart. OncoAlert Oncology Brothers

Nice slides to show comparison of ARPIs available. Do u use low dose Abiraterone with food ? I do. Also repeat after me ARPI dose not work after ARPI . OncoAlert Yakup Ergün Yüksel Ürün Oncology Brothers